Tandem Diabetes Care (TNDM) EBIAT (2016 - 2025)
Tandem Diabetes Care (TNDM) has disclosed EBIAT for 13 consecutive years, with -$589000.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 178.01% year-over-year to -$589000.0, compared with a TTM value of -$204.7 million through Dec 2025, down 113.18%, and an annual FY2025 reading of -$204.7 million, down 113.18% over the prior year.
- EBIAT was -$589000.0 for Q4 2025 at Tandem Diabetes Care, up from -$21.2 million in the prior quarter.
- Across five years, EBIAT topped out at $10.8 million in Q4 2021 and bottomed at -$130.6 million in Q1 2025.
- Average EBIAT over 5 years is -$30.1 million, with a median of -$22.2 million recorded in 2024.
- The sharpest move saw EBIAT skyrocketed 161.59% in 2021, then tumbled 945.18% in 2022.
- Year by year, EBIAT stood at $10.8 million in 2021, then plummeted by 246.67% to -$15.9 million in 2022, then plummeted by 89.26% to -$30.0 million in 2023, then surged by 102.52% to $755000.0 in 2024, then tumbled by 178.01% to -$589000.0 in 2025.
- Business Quant data shows EBIAT for TNDM at -$589000.0 in Q4 2025, -$21.2 million in Q3 2025, and -$52.4 million in Q2 2025.